Hepatitis - people are not aware of the danger!

Content


Hepatitis - people are not aware of the dangerAn opinion poll conducted inSeptember-October 2013 on the initiative of the company Janssen NV Pharmaceuticals (Janssen), with the support of the International Alliance of Hepatitis (World Hepatitis Alliance, WHA), the European Association of patients with liver disease (European Liver Patients Association, ELPA) and the International Association for Research on Cancer liver (International liver Cancer Association, ILCA)1 , Seized more than 1,000 Russians over 18 years. Studies have shown a lack of public awareness about hepatitis and its consequences, in particular the risk of liver cancer - the sixth most common cancer and the third leading cause of death worldwide2.

The survey results indicate that depressingthe situation with public awareness of these dangerous diseases. Only every 7th person knowledgeable about viral hepatitis and infection methods, the vast majority of the respondents have about them a minimum representation (72%) or do not know anything (13%). Hepatitis B - a viral inflammatory disease of the liver, provoking a short-term or acute infection. Viruses Hepatitis B, C and D can lead to the development of chronic hepatitis - lasting infectious disease that threatens serious complications, such as cirrhosis (scarring of the liver), liver failure and liver cancer. Currently, up to 90% of persons infected with hepatitis B virus and hepatitis C, no know that sick3.

In spite of the high mortality from liver cancer,Only 21% of people know that the main cause of cancer lesions of the liver cells it is viral hepatitis. According to the medical community, a total of more than 500,000 cases of liver cancer (accounting for 90%) are related to infection with hepatitis viruses B and C4.

The majority (4 of 5 people) are aware thatviral hepatitis transmitted with blood or other body fluids of an infected person, but far fewer people are aware that hepatitis B can be transmitted through sexual contact, in medical institutions while using non-sterile instruments, tattoo parlor, while using common household items with an infected person, and so on. d. However, in Russia, in comparison with European countries, only 4% of respondents do not know that hepatitis B and C are transmitted is from person to person.

General awareness of the availability ofmethods of prevention and treatment of viral hepatitis is not enough - according to the survey, people often make mistakes in their judgments about the symptoms and treatment options for viral hepatitis B and C. For example, one in four respondents did not know whether to physically manifest symptoms of hepatitis B. It is only half of the citizens informed about the possibilities of prevention and preventing this disease. In the case of hepatitis C is even worse - every second believes that the symptoms in this case are clearly visible, and 4 out of 10 respondents also believe that there is prevention of the disease. Thus if every second Russian knows about the possibility of vaccine in the case of hepatitis B, then only every third informed about the absence of vaccination against hepatitis C.

According to the survey:

  • 31% of respondents did not know whether there is a vaccine against hepatitis B, and 20% wrong in the fact that there is no such vaccines;
  • 15% of the population believe that hepatitis B, there is no treatment;
  • 36% wrong in the existence of a vaccine against hepatitis C, and only 31% believe that this virus no vaccine;
  • 20% of respondents believe that today there are no treatments available for hepatitis C, a further 23% do not know anything about it;
  • 44% of respondents did not know that hepatitis C - is a curable disease.

The level of awareness of Russians about viral hepatitis is very low, and raise serious concerns of physicians and representatives of public organizations.

"Given the direct dependence of the development of liver cancerfrom infection with hepatitis B virus, efforts should be made in the fight against the disease - said the chief gastroenterologist of Health Department of the City of Moscow, Head of the Department of Hepatology TSNIIG, Professor MD IG Bakulin. "First of all, it is important to the state's attention to thisproblem. Priorities: the creation of a register of patients, improve diagnostic level, implementation of the modern methods of treatment, which can significantly increase the number of cured patients, regular monitoring of the quality and timeliness of patient care. All these measures will in the near future to cure chronic hepatitis C as a disease and save the lives of many people".


"The problem is widespread viralHepatitis concerns not the individual, but the whole society. It is necessary to carry out prevention of hepatitis spread through broad public awareness of risk factors and treatment options. We believe that our country should be implemented measures of state support for the citizens infected with viral hepatitis, as law recognizes the socially significant diseases "
- Says co-chair of the Russian Union of patient associations, the president of the Russian Society of Hemophilia YA Zhulev.

If you think that you or someone in your family may be at risk of hepatitis infection, it is important to discuss this with your doctor!

reference Information


About the study

The results were obtained during an online poll,conducted by Edelman Berland (in partnership with ICM), in the period of September 20-October 15, 2013. The survey covered more than 5,000 persons, not related to medicine, aged 18 and over in four countries: the UK, Spain, Russia and Turkey. The purpose of this study - to determine the degree of awareness and perception of hepatitis B and hepatitis C and their relationship with society cancer of the liver.


About the month of liver cancer awareness

Month awareness of liver cancer (Liver CancerAwareness Month, LCAM) - Healthcare is an annual campaign (held in October), organized by the charitable organizations involved in liver cancer patients and other groups specializing in this disease organizations. The campaign aims to raise awareness about the diseases that contribute to the development of liver cancer, and existing preventive measures, as well as to attract funding for further research its causes, prevention, diagnosis, treatment and recovery.


About Hepatitis C

Hepatitis C - is an infectious disease of the liver,which is transmitted through contact with blood or other body fluids of an infected person, and at the initial stage is usually asymptomatic6. Since the world of about 150 millions of people infected with the virus6And each year 3-4 million are infected for the first time, hepatitis C is a heavy burden on patients and society12. According to estimates, the disease leads to the death of more than 499,000 people worldwide each year, representing approximately 1% of all deaths10. This is a major global cause of cirrhosis and liver cancer13, And cirrhosis develops in approximately 20-30% of patients14, 7% of which is subsequently liver cancer arises11. It is estimated that the annual costs associated with hepatitis C (treatment and loss of health), only in the United States account for more than $ 1 billion15.


About the European Association of patients with liver diseases

European Association for patients with diseasesliver (European Liver Patients Association, ELPA) arose from a desire to groups of patients with liver diseases in Europe share the experience of the approaches used in different countries. In June 2004, a group of patients from 10 European and Mediterranean countries met to create the association. Formally ELPA has been organized in Paris on 14 April 2005 during the annual conference of the European Association for the Study of the Liver (European Association for the Study of the Liver, EASL) and now includes 30 members from 24 countries. The purpose ELPA is to promote the interests of people with liver disease, in particular, the extent of coverage problems, help in raising awareness and in prevention, problem solving little attention to diseases of the liver as compared to other areas of medicine such as heart disease, sharing experiences of successful initiatives, work with professional bodies such as EASL, to ensure the harmonization of methods of treatment and care in Europe and to achieve the highest standards.


About the International Association for the Study of Liver Cancer

The International Association for the Study of Liver Cancer(International Liver Cancer Association, ILCA) - is the only international association dedicated solely to the study of liver cancer for experts in all related disciplines. ILCA is committed to improving the pathogenesis research, prevention and treatment of liver cancer by promoting innovative pathogenetic, diagnostic and therapeutic interventions for liver cancer, which uses a transverse approach to research and brings together scientists, physicians, and professionals from related fields close.


About the International Alliance against hepatitis

International Alliance Against hepatitis (WorldHepatitis Alliance, WHA) - a non-profit non-governmental organization (NGO). It includes more than 170 organizations working in the field of viral hepatitis, and from all regions of the world. WHA run by patients, and the organization itself is aimed at the needs of patient community. Through a commitment to this approach, the right to vote in this alliance have only patient organizations. Internationally WHA expresses the opinion of 500 million people worldwide are living with hepatitis. Ultimately, the purpose of the WHA is to work with governments, by raising awareness, improving the prevention, care, support, and improve access to treatment for the elimination of these diseases on the planet. In different countries of the world WHA holds guidance and support measures are available to reduce the number of deaths from hepatitis B and improve the lives of patients.

Bibliography

  1. Ferlay J, Shin HR, Bray F, Forman D et al. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet] Lyon, France: International Agency for Research on Cancer, 2010. Available at: http://globocan.iarc.fr.
  2. Parkin, DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer. 2006; 18 (12): 3030-44.
  3. World Hepatitis Alliance. Abou Viral Hepatitis. Available at: http://www.worldhepatitisalliance.org/en/about-viral-hepatitis.html.
  4. ELPA. Liver Cancer Prevention: Getting viral hepatitis under control. European Week Against Cancer 2013. May 29, 2013. Available on http://www.easl.eu/assets/application/files/785d69feecfb1ba_file.pdf site.
  5. World Health Organization. Media Centre: Hepatitis B. July 2013. Available at: http://www.who.int/mediacentre/factsheets/fs204/en/.
  6. World Health Organization. Media Centre: Hepatitis C. July 2013. Available at: http://www.who.int/mediacentre/factsheets/fs164/en/.
  7. Health Consumer Powerhouse. Euro Hepatitis Index 2012 Report. Available on http://www.hep-index.eu/tl_files/hep-index/download/Report_Hepl_HCP_121103.pdf site.
  8. Economist Intelligence Unit. The Silent Pandemic: Tackling Hepatitis C with Policy Innovation. January 2013.
  9. CDC. Hepatitis B. Available at: http://www.cdc.gov/hepatitis/HBV/HBVfaq.htm#overview.
  10. Global Burden of Disease Study 2010. The Lancet. 2012. Available at: http://www.thelancet.com/themed/global-burden-of-disease.
  11. Blachier M, Leleu H, Peck-Radosavljevic M, et al. The Burden of liver disease in Europe: A review of available epidemiological data. European Association for the Study of the Liver in 2013.
  12. World Health Organization. State of the art of vaccine research and development. Viral Cancers. Available at: http://www.who.int/vaccine_research/documents/Viral_Cancers.pdf. Last October 2013
  13. Rosen HR. Clinical practice. Chronic hepatitis C infection. N Engl J Med. 2011; 364 (25): 2429-38.
  14. Hep C Trust: Overview of Stages. Available at: http://www.hepctrust.org.uk/Hepatitis_C_Info/Stages+of+Hepatitis+C/Overview+of+the+stages. Last in October 2013.
  15. El Khoury A, Klimack W, Wallace C, et al. Economic burden of hepatitis C-associated diseases in the United States. J Viral Hep. 2012; 19: 153-160.

Leave a reply